U.K. National Institute for Health and Care Excellence CEO Andrew Dillon wrote a letter to The Times calling on drugmakers to question the costs of developing new treatments. The move was made in response to a comment piece by Ian King, the business editor of the newspaper, which warned that the pharmaceutical industry will end drug development in the country unless the agency stops denying patients access to medicines because they have too many harmful side effects or are too expensive. "I suspect that the research and clinical environment here holds too many advantages for companies to do that, though it is certainly the case that there is a global market for life sciences R&D and the U.K. has to compete hard to win its share," Dillon wrote in the letter.

Full Story:
PharmaTimes (U.K.)

Related Summaries